Antiviral Activity of a Phosphorothioate Oligonucleotide Complementary to RNA of the Human Cytomegalovirus Major Immediate-early Region

Overview

Journal Antimicrob Agents Chemother

Publisher American Society for Microbiology

Specialty Pharmacology

Date 1993 Sep 1

PMID 8239610

Citations 46

Authors

R F Azad

V B Driver

K Tanaka

R M Crooke

K P Anderson

Affiliations

Soon will be listed here.

Abstract

Phosphorothioate oligonucleotides complementary to mRNA of the human cytomegalovirus (HCMV) DNA polymerase gene or to RNA transcripts of the major immediate-early regions 1 and 2 (IE1 and IE2) of HCMV were evaluated for antiviral activity in a 96-well immunoassay with primary human dermal fibroblasts as host cells. Oligonucleotides complementary to RNA of the IE2 region exhibited the most potent antiviral activity. One of these oligonucleotides, ISIS 2922, was at least 30-fold more potent than the nucleoside analog, ganciclovir, with a 50% effective concentration of 0.37 microM in the 96-well immunoassay. In an infectious virus yield reduction assay, ISIS 2922 and ganciclovir reduced production of infectious virus by 2 log units at concentrations of 2.2 and 36 microM, respectively. A control oligonucleotide showed no inhibition of virus production at concentrations as high as 3 microM. ISIS 2922 reduced IE protein synthesis in HCMV-infected cells in a dose-dependent manner which correlated with antiviral activity. The antiviral activity of ISIS 2922 was not due to oligonucleotide-induced cytotoxicity since effects on cell viability or proliferation were observed only at concentrations well in excess of effective antiviral concentrations. The specificity and potency of ISIS 2922 suggest that it may be useful for the treatment of cytomegalovirus disease in humans.

Citing Articles

Oligonucleotide therapies for nonalcoholic steatohepatitis.

Li S, Xiong F, Zhang S, Liu J, Gao G, Xie J Mol Ther Nucleic Acids. 2024; 35(2):102184.

PMID: 38665220 PMC: 11044058. DOI: 10.1016/j.omtn.2024.102184.

Detection of the phosphorothioate oligonucleotide fomivirsen using a ligase detection reaction with polymerase chain reaction.

Harikai N, Kakuda H, Uchiyama T, Yamamoto T, Zaima K, Shinomiya K Anal Sci. 2024; 40(5):965-971.

PMID: 38523232 DOI: 10.1007/s44211-024-00539-1.

Assessing the gene silencing potential of AuNP-based approaches on conventional 2D cell culture versus 3D tumor spheroid.

Oliveira B, Fernandes A, Viana Baptista P Front Bioeng Biotechnol. 2024; 12:1320729.

PMID: 38410164 PMC: 10894999. DOI: 10.3389/fbioe.2024.1320729.

The Medicinal Chemistry of Artificial Nucleic Acids and Therapeutic Oligonucleotides.

Bege M, Borbas A Pharmaceuticals (Basel). 2022; 15(8).

PMID: 35893733 PMC: 9330994. DOI: 10.3390/ph15080909.

Deliver the promise: RNAs as a new class of molecular entities for therapy and vaccination.

Yu A, Tu M Pharmacol Ther. 2021; 230:107967.

PMID: 34403681 PMC: 9477512. DOI: 10.1016/j.pharmthera.2021.107967.

References

Myers J, Spencer Jr H, Watts J, GREGG M, Stewart J, Troupin R . Cytomegalovirus pneumonia after human marrow transplantation. Ann Intern Med. 1975; 82(2):181-8. DOI: 10.7326/0003-4819-82-2-181. View

Gao W, Hanes R, Stein C, Cohen J, Cheng Y . Inhibition of herpes simplex virus type 2 growth by phosphorothioate oligodeoxynucleotides. Antimicrob Agents Chemother. 1990; 34(5):808-12. PMC: 171696. DOI: 10.1128/AAC.34.5.808. View

Rubin R, Cosimi A, Russell P, Hirsch M . Infectious disease syndromes attributable to cytomegalovirus and their significance among renal transplant recipients. Transplantation. 1977; 24(6):458-64. DOI: 10.1097/00007890-197712000-00010. View

Marker S, Howard R, Simmons R, Kalis J, Connelly D, Najarian J . Cytomegalovirus infection: a quantitative prospective study of three hundred twenty consecutive renal transplants. Surgery. 1981; 89(6):660-71. View

Oberg B . Antiviral effects of phosphonoformate (PFA, foscarnet sodium). Pharmacol Ther. 1982; 19(3):387-415. DOI: 10.1016/0163-7258(82)90074-2. View

Stenberg R, Witte P, Stinski M . Multiple spliced and unspliced transcripts from human cytomegalovirus immediate-early region 2 and evidence for a common initiation site within immediate-early region 1. J Virol. 1985; 56(3):665-75. PMC: 252635. DOI: 10.1128/JVI.56.3.665-675.1985. View

Denizot F, Lang R . Rapid colorimetric assay for cell growth and survival. Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability. J Immunol Methods. 1986; 89(2):271-7. DOI: 10.1016/0022-1759(86)90368-6. View

Zamecnik P, Goodchild J, Taguchi Y, SARIN P . Inhibition of replication and expression of human T-cell lymphotropic virus type III in cultured cells by exogenous synthetic oligonucleotides complementary to viral RNA. Proc Natl Acad Sci U S A. 1986; 83(12):4143-6. PMC: 323687. DOI: 10.1073/pnas.83.12.4143. View

Heilbronn R, Jahn G, Burkle A, Freese U, Fleckenstein B, zur Hausen H . Genomic localization, sequence analysis, and transcription of the putative human cytomegalovirus DNA polymerase gene. J Virol. 1987; 61(1):119-24. PMC: 255217. DOI: 10.1128/JVI.61.1.119-124.1987. View

10.

Kouzarides T, Bankier A, Satchwell S, WESTON K, Tomlinson P, Barrell B . Sequence and transcription analysis of the human cytomegalovirus DNA polymerase gene. J Virol. 1987; 61(1):125-33. PMC: 255219. DOI: 10.1128/JVI.61.1.125-133.1987. View

11.

Agris C, Blake K, Miller P, Reddy M, Tso P . Inhibition of vesicular stomatitis virus protein synthesis and infection by sequence-specific oligodeoxyribonucleoside methylphosphonates. Biochemistry. 1986; 25(20):6268-75. DOI: 10.1021/bi00368a065. View

12.

Lemaitre M, Bayard B, Lebleu B . Specific antiviral activity of a poly(L-lysine)-conjugated oligodeoxyribonucleotide sequence complementary to vesicular stomatitis virus N protein mRNA initiation site. Proc Natl Acad Sci U S A. 1987; 84(3):648-52. PMC: 304272. DOI: 10.1073/pnas.84.3.648. View

13.

Henderly D, Freeman W, Causey D, RAO N . Cytomegalovirus retinitis and response to therapy with ganciclovir. Ophthalmology. 1987; 94(4):425-34. DOI: 10.1016/s0161-6420(87)33454-2. View

14.

Hermiston T, Malone C, Witte P, Stinski M . Identification and characterization of the human cytomegalovirus immediate-early region 2 gene that stimulates gene expression from an inducible promoter. J Virol. 1987; 61(10):3214-21. PMC: 255900. DOI: 10.1128/JVI.61.10.3214-3221.1987. View

15.

Matsukura M, Shinozuka K, Zon G, Mitsuya H, Reitz M, Cohen J . Phosphorothioate analogs of oligodeoxynucleotides: inhibitors of replication and cytopathic effects of human immunodeficiency virus. Proc Natl Acad Sci U S A. 1987; 84(21):7706-10. PMC: 299369. DOI: 10.1073/pnas.84.21.7706. View

16.

Pizzorno M, OHare P, Sha L, LaFemina R, Hayward G . trans-activation and autoregulation of gene expression by the immediate-early region 2 gene products of human cytomegalovirus. J Virol. 1988; 62(4):1167-79. PMC: 253124. DOI: 10.1128/JVI.62.4.1167-1179.1988. View

17.

Jacobson M, Mills J . Serious cytomegalovirus disease in the acquired immunodeficiency syndrome (AIDS). Clinical findings, diagnosis, and treatment. Ann Intern Med. 1988; 108(4):585-94. DOI: 10.7326/0003-4819-108-4-585. View

18.

Agrawal S, Goodchild J, Civeira M, Thornton A, SARIN P, Zamecnik P . Oligodeoxynucleoside phosphoramidates and phosphorothioates as inhibitors of human immunodeficiency virus. Proc Natl Acad Sci U S A. 1988; 85(19):7079-83. PMC: 282127. DOI: 10.1073/pnas.85.19.7079. View

19.

Jabs D, Enger C, Bartlett J . Cytomegalovirus retinitis and acquired immunodeficiency syndrome. Arch Ophthalmol. 1989; 107(1):75-80. DOI: 10.1001/archopht.1989.01070010077031. View

20.

Stenberg R, Depto A, Fortney J, Nelson J . Regulated expression of early and late RNAs and proteins from the human cytomegalovirus immediate-early gene region. J Virol. 1989; 63(6):2699-708. PMC: 250760. DOI: 10.1128/JVI.63.6.2699-2708.1989. View